Immunome (NASDAQ:IMNM) Earns “Outperform” Rating from Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research note issued on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock. Wedbush‘s target price suggests a potential upside of 86.47% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of Immunome in a research note on Tuesday. William Blair began coverage on Immunome in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Alliance Global Partners began coverage on Immunome in a research note on Monday, September 21st. They set a “buy” rating and a $32.00 price objective on the stock. Stifel Nicolaus began coverage on Immunome in a research report on Wednesday, September 30th. They set a “hold” rating and a $24.00 target price for the company. Finally, Truist Financial raised their target price on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and a consensus price target of $34.25.

Immunome Trading Up 4.9%

Shares of IMNM traded up $0.88 during trading hours on Tuesday, reaching $18.77. The stock had a trading volume of 1,226,154 shares, compared to its average volume of 1,365,339. Immunome has a 12 month low of $14.64 and a 12 month high of $30.06. The firm has a 50-day simple moving average of $23.22 and a 200 day simple moving average of $22.51. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -7.42 and a beta of 2.55.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, equities analysts forecast that Immunome will post -2.48 EPS for the current year.

Insider Buying and Selling

In other Immunome news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. The trade was a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares of the company’s stock, valued at $1,263,682.94. The trade was a 64.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 223,368 shares of company stock worth $5,747,142 in the last quarter. 7.21% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. Allworth Financial LP bought a new position in shares of Immunome during the second quarter valued at approximately $25,000. Integrated Wealth Concepts LLC bought a new position in shares of Immunome during the second quarter valued at approximately $27,000. KBC Group NV bought a new position in shares of Immunome during the first quarter valued at approximately $60,000. GK Wealth Management LLC bought a new position in shares of Immunome during the third quarter valued at approximately $71,000. Finally, Sterling Capital Management LLC raised its holdings in shares of Immunome by 840.0% during the third quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock valued at $75,000 after acquiring an additional 3,108 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.